Evidence mapPaperPMID 38973992Full record

ReviewBioactive materials2024

Liver tissue engineering using decellularized scaffolds: Current progress, challenges, and opportunities.

Kamal H Hussein, Boyukkhanim Ahmadzada, Julio Cisneros Correa, Ahmer Sultan, Silvana Wilken, Bruce Amiot, Scott L Nyberg

Abstract readReview
In one paragraph

Review in Bioactive materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Lessons Learned from Liver-on-Chip Platform.Annals of biomedical engineering · 2025
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. 3D bioprinting for bile duct tissue engineering: current status and prospects.Frontiers in bioengineering and biotechnology · 2025
    Review
  17. Article
  18. Supercritical COACS omega · 2024
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kamal H HusseinDepartment of Surgery, Mayo Clinic, Rochester, MN, United States.
Boyukkhanim AhmadzadaDepartment of Surgery, Mayo Clinic, Rochester, MN, United States.
Julio Cisneros CorreaDepartment of Surgery, Mayo Clinic, Rochester, MN, United States.
Ahmer SultanDepartment of Surgery, Mayo Clinic, Rochester, MN, United States.
Silvana WilkenDepartment of Surgery, Mayo Clinic, Rochester, MN, United States.
Bruce AmiotDepartment of Surgery, Mayo Clinic, Rochester, MN, United States.
Scott L NybergDepartment of Surgery, Mayo Clinic, Rochester, MN, United States.

Funding

NIDDK NIH HHS R01 DK106667
6 · The paper itself

Abstract

Liver transplantation represents the only definitive treatment for patients with end-stage liver disease. However, the shortage of liver donors provokes a dramatic gap between available grafts and patients on the waiting list. Whole liver bioengineering, an emerging field of tissue engineering, holds great potential to overcome this gap. This approach involves two main steps; the first is liver decellularization and the second is recellularization. Liver decellularization aims to remove cellular and nuclear materials from the organ, leaving behind extracellular matrices containing different structural proteins and growth factors while retaining both the vascular and biliary networks. Recellularization involves repopulating the decellularized liver with appropriate cells, theoretically from the recipient patient, to reconstruct the parenchyma, vascular tree, and biliary network. The aim of this review is to identify the major advances in decellularization and recellularization strategies and investigate obstacles for the clinical application of bioengineered liver, including immunogenicity of the designed liver extracellular matrices, the need for standardization of scaffold fabrication techniques, selection of suitable cell sources for parenchymal repopulation, vascular, and biliary tree reconstruction.

Indexed as

Biliary reconstructionBioengineered liverDecellularizationRecellularizationReendothelialization

Identifiers

PMID38973992
PMCPMC11226731

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.